Close mobile menu×
Close mobile menu

Larisa J. Geskin, MD

Board Certifications: 
Dermatology
Expertise in: 
Cancer Care, Melanoma, Skin Cancer
Accepting New Patients
Profile Headshot

Appointments

Book Online

Participating DocASAP doctors have online booking available without the need for a Connect Patient Portal account.

Phone Appointments

New and Existing Patients: 

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor

Board Certifications

  • Dermatology

Clinical Expertise

  • Cutaneous Lymphoma
  • Dermatologic Oncology
  • General dermatology
  • Non-Melanoma Skin Cancer
  • Skin Cancer
  • Skin Cancer Surgery

Education & Training

  • 1995 Albert Einstein College of Medicine
  • MD, 1998 University of Pittsburgh School Of Medicine
  • Residency: 2001 University of Pittsburgh Medical Center
  • Fellowship: 2003 University of Pittsburgh Medical Center

About Larisa Geskin

dr._larisa_geskin_md_-_dermatologist_at_columbiadoctors

Dr. Larisa Geskin is an Associate Professor of Dermatology at Columbia University Medical Center and Director of the Comprehensive Skin Cancer Center (CSCC) at the Division of Cutaneous Oncology in the Department of Dermatology.

She is a world-renowned specialist in the diagnosis and management of cutaneous lymphomas and other cancers of the skin. Her other areas of expertise include melanoma screening, prevention, medical and surgical therapy, and management of high risk for skin cancer populations. Dr. Geskin is using state-of-the-art methods in melanoma screening and surveillance including Mole Mapping (body mapping) and dermoscopy. She was involved in development of novel melanoma detection methods, including MelaFind among others. Dr. Geskin's team aims to provide multidisciplinary care to skin cancer patients, to conduct cutting edge clinical and basic science research, and to train medical students, residents and fellows in the area of cutaneous oncology.

Dr. Geskin completed her residency in Dermatology at University of Pittsburgh Medical Center (UPMC), and a two-year fellowship in cutaneous oncology at University of Pittsburgh Cancer Institute (UPCI) with Louis Falo, MD, PhD, Professor and Chairman, Department of Dermatology, UPMC, and with John Kirkwood, MD, Professor and Vice Chairman for Clinical Research, Director of the Melanoma Center at the UPCI.

She is a diplomat of the American Academy of Dermatology, member of the Society for Investigative Dermatology, the International Society for Cutaneous Lymphomas, and US Cutaneous Lymphomas Consortium. She authored over 30 peer-reviewed articles in the field of cutaneous oncology. Her research interest focuses on Cutaneous T-cell lymphoma (CTCL) and biomarkers discovery, genetic profiling and regulation, development of immunotherapy for melanoma and lymphoma.

Academic Titles

  • Associate Professor of Dermatology (in Medicine) at CUMC

Administrative Positions

  • Director, Cutaneous Oncology

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Primary
2
51 West 51st Street
Suite 390
New York, New York 10019
3
155 White Plains Road
Tarrytown, New York 10591

Research

Grants

RETROSPECTIVE ANALYSIS OF STANDARD-OF CARE IMAGING IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA TO DEVOLPE NEW LYMPH NODE RESPONSE CRITERIA BY USING NOVEL RADIOLOGICAL QUANTITATIVE TECHNIQUES. (P&S Industry Clinical Trial)

Jan 15 2020 - Jan 15 2025

ANOPEN LABEL, MULTI-COHORT, MULTI-CENTER PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T-CELL LYMPHOMA (P&S Industry Clinical Trial)

Oct 25 2019 - Oct 25 2024

SOLAR:A PHASE 2, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, ACTIVE COMPARATOR, MULTI-CENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBOMARSEN (MRG-106) IN SUBJECTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL), MYCOSIS FUNGOIDES (MF) SUBTYPE (P&S Industry Clinical Trial)

Sep 6 2019 - Sep 6 2024

A CLINICAL STUDY TO DEMONSTRATE SAFETY AND EFFICACY OF E7777 IN PERSISTENT OR RECURRENT CUTANEOUS T-CELL LYMPHOMA (P&S Industry Clinical Trial)

Aug 6 2018 - Aug 6 2023

APHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY OF TOPICAL SGX301 (SYNTHETIC HYPERICIN) AND FLUORESCENT BULB-LIGHT IRRADIATION FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (P&S Industry Clinical Trial)

May 1 2017 - May 30 2022

ADOUBLE BLIND, RANDOMIZED, VEHICLE CONTROLLED, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION, 0.5%, FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS (P&S Industry Clinical Trial)

Mar 8 2017 - Mar 8 2022

IMAGE-BASED DEEP LEARNING TO PREDICT MELANOMA RECURRENCE (Private)

Feb 1 2020 - Feb 1 2021

A NOVEL UV SIGNATURE FOR ASSESSING SKIN UC DAMAGE AND CANCER RISK (Private)

Jan 15 2019 - Jan 14 2021

PRECLINICAL EVALUATION OF VORINOSTAT IN ALOPECIA AREATA (Federal Gov)

Jul 18 2017 - Jun 30 2020

ROLE OF TOX AND STAT3 PATHWAYS IN THE PATHOGENESIS OF CUTANEOUS TCELL LYMPHOMA (Private)

May 1 2018 - Apr 30 2019

VALIDATION OF UV-RADIATION BIOMARKER PANEL FOR RISK OF UV-INDUCED SKIN CANCERS (Private)

May 1 2018 - Apr 30 2019

ROLE OF THE TOX-RUNX3 PATHWAY IN CUTANEOUS T-CELL LYMPHOMA (Private)

May 1 2017 - Apr 30 2018

OPEN LABEL MULTICENTER RANDOMIZED STUDY OF ANTI-CCR4 MONOCLONAL ANTIBODY KW-0761 (MOGANMULIZUMAB) VERSUS VORINOSTAT IN SUBJECTS WITH PREVIOUSLY TREATED CUTANEOUS T-CELL LYMPHOMA (P&S Industry Clinical Trial)

Feb 21 2013 - Feb 21 2018

A MULTIPLEX ASSAY FOR EARLY DETECTION OF CUTANEOUS T-CELL LYMPHOMA (Federal Gov)

Sep 1 2016 - Aug 31 2017

MOLECULAR PATHWAYS OF INERLEUKIN-13 IN CUTANEOUS T-CELL LYMPHOMA (Federal Gov)

Jul 1 2016 - Jun 30 2017

IDENTIFYING LONG NON-CODING RNAS THAT FUNCTION AS MICRORNA SPONGES DURING MELANOMA INITIATION (Private)

Feb 1 2016 - Jan 31 2017